The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PSTI | -13.89% | -94.73% | -44.49% | -100% |
| S&P | +15.06% | +95.03% | +14.29% | +665% |
Pluri, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The firm focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.
Promising results from a very small study caused shares of stem cell stocks to soar, but investors shouldn't get too carried away just yet.
The stem cell developer found a financing solution that won't dilute shareholders. Well, not immediately, anyway.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.40M | 314.6% |
| Gross Profit | $0.10M | 209.7% |
| Gross Margin | 24.12% | -8.2% |
| Market Cap | $38.77M | 24.5% |
| Market Cap / Employee | $0.31M | 0.0% |
| Employees | 127 | 19.8% |
| Net Income | -$7.77M | -32.5% |
| EBITDA | -$6.51M | -9.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $6.32M | -10.2% |
| Accounts Receivable | $0.32M | 31.1% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $6.10M | -79.0% |
| Short Term Debt | $27.95M | 4899.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -57.75% | -11.5% |
| Return On Invested Capital | -64.37% | 18.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$5.94M | -37.3% |
| Operating Free Cash Flow | -$5.22M | -20.9% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -6.31 | -4.46 | -2.98 | -8.60 | -89.87% |
| Price to Sales | 55.23 | 35.01 | 27.30 | 29.25 | -69.50% |
| Price to Tangible Book Value | -6.31 | -4.46 | -2.98 | -8.60 | -89.87% |
| Enterprise Value to EBITDA | -8.40 | -7.48 | -7.07 | -8.92 | 48.19% |
| Return on Equity | -173.6% | -231.1% | -310.6% | -1205.6% | - |
| Total Debt | $30.88M | $29.30M | $31.19M | $34.05M | 14.99% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
